Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Carbon monoxide as medicine? tiny trial tests inhaled gas for lung failure

NCT ID NCT04870125

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether inhaling low doses of carbon monoxide could be safe for people with severe lung injury caused by sepsis. Only 5 participants were enrolled before the study was stopped early. The goal was to see if a personalized dosing formula could safely achieve target carbon monoxide levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
inhaled carbon monoxide
What this could lead to
If it works, this could point toward a new way to treat severe lung inflammation in sepsis patients.
What could go wrong
This was a very early, small safety trial that was terminated early with only 5 participants. The results are too limited to draw any conclusions about effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

5 people

The number who actually took part.

Started

Dec 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients (age 18 and older) will be eligible for inclusion if they meet all of the following consensus criteria for sepsis and ARDS3,4 or if they meet the criteria for pneumonia as described below. * Patients with sepsis are defined as those with life-threatening organ dysfunction caused by a dysregulated host response to infection: 1. Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system 2. Increase in Sequential Organ Failure Assessment (SOFA) Score ≥ 2 over baseline * ARDS is defined when all four of the following criteria are met: 1. A PaO2/FiO2 ratio ≤ 300 with at least 5 cm H2O positive end-expiratory airway pressure (PEEP) 2. Bilateral opacities on frontal chest radiograph (not fully explained by effusions, lobar/lung collapse, or nodules) within 1 week of a known clinical insult or new or worsening respiratory symptoms 3. A need for positive pressure ventilation by an endotracheal or tracheal tube 4. Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor is present * Pneumonia (without ARDS or sepsis) will be defined as a unilateral or bilateral lung infiltrate on chest X-ray or chest CT (not fully explained by effusions, lobar/lung collapse or nodules) in the setting of receiving mechanical ventilation, a new suspected respiratory infection, an increase in SOFA score less than 2 at the time of randomization (baseline). * Pneumonia (with sepsis, without ARDS) will be defined as a unilateral or bilateral lung infiltrate on chest X-ray or chest CT (not fully explained by effusions, lobar/lung collapse or nodules) in the setting of receiving mechanical ventilation and a new suspected respiratory infection with an increase in SOFA score of ≥ 2 over baseline at the time of randomization. Pneumonia with bilateral opacities, PaO2/FiO2 ratio ≤ 300, or an increase in SOFA score greater than or equal to 2 over baseline will continue to be considered ARDS and sepsis. Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Age less than 18 years 2. Greater than 168 hours since ARDS onset 3. Pregnant or breastfeeding 4. Prisoner 5. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest) 6. No consent/inability to obtain consent or appropriate legal representative not available 7. Physician refusal to allow enrollment in the trial 8. Moribund patient not expected to survive 24 hours 9. No arterial line or central line/no intent to place an arterial or central line 10. No intent/unwillingness to follow lung protective ventilation strategy 11. Severe hypoxemia defined as SpO2 \< 95 or PaO2 \< 90 on FiO2 ≥ 0.9 12. Hemoglobin \< 7.0 g/dL 13. Subjects who are Jehovah's Witnesses or are otherwise unable or unwilling to receive blood transfusions during hospitalization 14. Acute myocardial infarction (MI) or acute coronary syndrome (ACS) within the last 90 days 15. Coronary artery bypass graft (CABG) surgery within 30 days 16. Angina pectoris or use of nitrates with activities of daily living 17. Severe cardiopulmonary disease classified as New York Heart Association (NYHA) class IV 18. Stroke (ischemic or hemorrhagic) within the prior 1 month, cardiac arrest requiring CPR within the prior 72 hours, or inability to assess mental status following cardiac arrest 19. Burns \> 40% total body surface area 20. Severe airway inhalational injury 21. Use of high frequency oscillatory ventilation 22. Use of extracorporeal membrane oxygenation (ECMO) 23. Use of inhaled pulmonary vasodilator therapy (eg. nitric oxide \[NO\] or prostaglandins) 24. Diffuse alveolar hemorrhage from vasculitis 25. Concurrent participation in other investigational drug study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Duke University Hospital

    Durham, North Carolina, 27710, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • New York-Presbyterian Brooklyn Methodist Hospital

    Brooklyn, New York, 11215, United States

  • Washington University

    St Louis, Missouri, 63110, United States

  • Weill Cornell Medical College

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.